LY007
Phase 1- Indications
- Cancer
Company intelligence / Profile preview
China Biotech Services Holdings provides precision medical diagnostic services using advanced laboratory technologies such as PCR. The company also offers tumor immune cell therapies, boron neutron capture therapy for cancer treatment, general health management solutions, insurance brokerage related to healthcare, pharmaceutical product distribution, logistics support in healthcare supply chains, and property investment. Its operations are primarily based in Hong Kong with a focus on both the local market and mainland China. No detailed clinical results or published pipeline data are available; the company appears to be focused on commercialized service offerings rather than proprietary drug development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on China Biotech Services Holdings.